TTR and polyneuropathy: Eplontersen shares a similar design and identical nucleobase sequence with inotersen, an ASO previously approved for the treatment of polyneuropathy of ATTR, but uses unique chemistry and GalNAc conjugation to specifically target hepatocytes, the main source of TTR in the body.671,672 This targeted approach allows eplontersen to be administered at lower doses and less frequently while still achieving efficacy.671,672